Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > COMMENTARY
COMMENTARY
-
June 7, 2004
-
May 24, 2004
- BULLETIN
May 24, 2004
- Brand Equity in the Pharmaceutical Industry
March 8, 2004
- <Special Contribution> Breakthrough Candidates from Japanese Pharmaceutical Industry in 2004 (2)
March 8, 2004
-
March 1, 2004
- Pursuing the Value of the Japanese Pharm Industry (2)
February 9, 2004
- <New Series> Pursuing the Value of the Japanese Pharm Industry (1)
January 19, 2004
- <Special Contribution> Happy New Year to Japanese Pharmaceutical Stocks!
January 12, 2004
- <Special Contribution> Global Products Enhance Dominance in Japan with Local Products Confined to Niche Markets
January 12, 2004
-
November 10, 2003
- <Special Contribution>
November 3, 2003
- <Special Contribution>
September 1, 2003
- Forecasting the Hypertensives Market: A Look Five Years Ahead Sugio Seko President, Pharma Marketing Survey Research Laboratory
August 11, 2003
-
June 9, 2003
-
May 12, 2003
-
March 24, 2003
-
January 20, 2003
- < Special Contribution >
January 13, 2003
- BARKER ON DRUGS
December 23, 2002
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…